The 23rd Congress of the European Hematological Association (EHA) 2018 in Stockholm, Sweden, saw many researchers presenting the newest data…
Browsing: Multiple Myeloma
Pomalidomide combinations in randomized trials are generating exciting data for relapsed/refractory multiple myeloma (MM). Here, Meletios Dimopoulos, MD, from the…
Novel strategies are required to move from simply controlling multiple myeloma (MM), to overcoming it and acheiving long-term remissions in…
Bruno Paiva, PhD, from the University of Navarra, Navarra, Spain, shares insights into multiple myeloma (MM) from the 23rd congress…
Monoclonal antibodies are an exciting theapeutic avenue for hematological cancers, including multiple myeloma (MM). Here, Niels van de Donk, MD,…
There are an increasing amount of promising targeted therapies being investigated for multiple myeloma (MM). In this interview, Niels van…
The clinical significance of smoldering multiple myeloma (MM) is, as of recently, becoming much more important, especially in those patients…
Speaking from the 1st European Myeloma Network (EMN) Meeting 2018, held in Turin, Italy, Francesca Gay, MD, of the University…
The progression of multiple myeloma (MM) can be monitored by determing what stage a patient is at; most notably, the…
Relapse often leads to difficulties in MM treatment, as patients may have developed resistance to a previous therapy. While the…
The progression of multiple myeloma (MM) can be monitored by determing what stage a patient is at; most notably, the…
Despite the constant research and drug development going on in the field of multiple myeloma (MM), a cure is still…
While the European Society for Medical Oncology (ESMO) provides guidelines for patient treatment after initial relapse, these are not always…
Robert Kyle, MD, of the Mayo Clinic, Rochester, MN, talks about examples of new therapies that are currently under development…
Although multiple myeloma (MM) has been known to physicians since the 1840s, effective treatments were not developed until much later.…
Phase III trials EMN441 (NCT01091831) and EMN01 (NCT01093196) both investigated progression-free survival (PFS), overall survival (OS) and time to next…
There are currently no concrete guidelines for how to use measurable residual disease (MRD) status to inform treatment decisions in…
The selective proteasome inhibitor carfilzomib has previously shown efficacy in terms of progression-free survival (PFS) for relapsed multiple myeloma (MM).…
The 23rd Congress of the European Hematology Association (EHA) 2018, held in Stockholm, Sweden, saw many researchers reporting their most…
Although treatments for multiple myeloma (MM) are constantly improving, ~25% of patients still have poor outlooks. We spoke to Guy…
The prognosis for patients with relapsed/refractory multiple myeloma (MM) is usually poor. In this video, Francesca Gay, MD, from the…
Measurable residual disease (MRD) is used as a prognostic indictor in a variety of hematological maliganancies, including multiple myeloma (MM).…
The RVD chemotherapy regimen combines lenalidomide, bortezomib, and dexamethasone, and is recognized by the European Society for Medical Oncology in…
Hareth Nahi, MD, of the Karolinska Institutet, Stockholm, Sweden, discusses the association between drug cost and toxicity at the 23rd…
The field of multiple myeloma (MM) has seen an influx of exciting new therapies. Here, Guy Pratt, MD, FRCP, FRCPath,…
In this interview at the 23rd Congress of European Haematology Association (EHA) 2018, held in Stockholm, Sweden, Gareth Morgan, MD,…
The FORTE trial (NCT02203643) aimed to compare responses to carfilzomib when combined with lenalidomide-dexamethasone (KRd) or with cyclophosphamide-dexamethasone (KCd) for…
Measurable residual disease (MRD) can be detected using two main techniques: next-generation sequencing and flow cytometry. Here, Bruno Paiva, PhD,…
Multiple myeloma (MM) is known to have a dysregulatory effect on the immune system; however, preclinical trials have shown that…
A picture can say a thousand words and, in this case, it is all too true; understanding tumour metabolism, bone…
Although the rates of progression-free survival are steadily increasing, the majority of multiple myeloma (MM) patients still face relapse. Here,…
Maria-Victoria Mateos, MD, PhD, from the University Hospital of Salamanca, Salamanca, Spain, discusses clinical trials that are currently investigating the…
After promising results form the CHAMPION 1 study (NCT01677858), which increased median progression-free survival to >1 year for relapsed/refractory multiple…
CAR T-cell therapy has proven to be a highly effective, breakthrough therapy for treating acute lymphoblastic leukemia and acute myeloid…
Speaking from the American Society of Oncology (ASCO) 2018 Annual Meeting in Chicago, IL, Nina Shah, MD, from the University…
Currently there is a good variety of treatments available for patients with relapsed multiple myeloma (MM). Here, Rakesh Popat, BSc,…
Data from the ENDEAVOUR trial (NCT01568866) has shown that using carfilzomib plus dexamethasone (Kd) is more effective in treating relapsed/refractory…
In this interview, recorded at the British Society for Haematology (BSH) 2018 Annual Meeting in Liverpool, UK, Rakesh Popat, BSc,…
Tumor suppressor gene TP53 is associated with aggressive disease activity when inactivated in a variety of tumor types, including multiple…
Treatment of multiple myeloma (MM) has improved greatly over the past few years; however, certain patients remain at high risk…
Tumor suppressor gene TP53 is associated with aggressive disease activity when inactivated in a variety of tumor types, including multiple…
Guy Pratt, MD, FRCP, FRCPath, of University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK, discusses recent guideline changes within multiple…
Challenges are often encountered when implementing guidelines into clinical practice. Here, Guy Pratt, MD, FRCP, FRCPath, of the University Hospitals…
Monoclonal antibody therapy has been around for a long while, but recent technological advancements have allowed for more tailored and…
With the impressive results from initial trials using CAR T-cells, excitement surrounding this modality as a curative therapy was high.…
In this interview, Faith Davies, MD, MRCP, MRCPath, FRCPath, from UAMS Myeloma Institute, Little Rock, AR, discusses the various drugs…
Ajai Chari, MD, Mt. Sinai, explains Isatuximab, Carfilzomib & Dexamethasone | Phase 1 Study Combining Drugs at Annual Meeting 2018
Ray Comenzo, MD, Tufts Medical Center, explains Daratumumab in Subcutaneous Form is Safe | Can Benefit Relapsed Light-Chain Amyloid at…
Ajai Chari, MD, Mt. Sinai, talks about Getting Regimens Approved | Avoid Insurance & Regulatory Barriers at Annual Meeting 2018
Ray Comenzo, MD, Tufts Medical Center, explains Earlier Diagnosis for SMM or MGUS | At Risk of Progressing to Light-chain…